Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH?
2026-10-11 23:09
•Sara Appino •The Motley Fool
•••• •••••••• Axe Cap view
IBB vs IYH: Which Healthcare ETF Fits Your SA Portfolio?
Biotech sparks big returns, but broad healthcare offers steadier exposure for South African investors.
The biotech-heavy IBB has dazzled with a 38% return over the past year, boosted by FDA approvals and takeover buzz. Problem? It’s volatile, with big downside swings that can shake even seasoned nerves. On the other hand, IYH spreads risk across 100+ healthcare firms including giants like LLY (leading GLP-1 innovation) and JNJ, offering a smoother ride, better dividends, and lower fees. For South African investors watching rand volatility and domestic equities, the lower-risk IYH aligns better with a cautious approach. The rand itself might face pressure if global risk appetite changes, so a steady US dollar healthcare play helps balance local market fluctuations. That said, if you can stomach the ups and downs and believe biotech breakthroughs will keep coming, IBB could pay off handsomely. But don’t bet on biotech momentum alone — regulatory setbacks or market rotations toward value stocks could knock IBB hard. this is just our opinion and not financial advice
Favor IYH for diversified, dividend-paying healthcare exposure paired with less volatility. Only consider IBB if you have a strong risk appetite and a view that biotech innovation continues accelerating.
- IBB
- IYH
- USD/ZAR
- Biotech volatility and regulatory hurdles impacting IBB
- Rand depreciation amplifying currency risk in dollar-denominated healthcare ETFs
6/10
The article compares two healthcare ETFs: IBB (biotech-focused) and IYH (broad healthcare). IBB has delivered stronger 1-year returns (38% vs 17.4%) but exhibits higher volatility and deeper drawdowns. IYH offers lower costs, higher dividend yield, and broader diversification, making it better for most long-term investors, while IBB suits those with conviction in biotech momentum who can tolerate volatility.
Our take is based on reporting first published by The Motley Fool.